(11S)-11-[(benzyloxy)methyl]-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinoline | 898818-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (11S)-11-[(benzyloxy)methyl]-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinoline
• 英文别名: (16S)-16-(phenylmethoxymethyl)-14-oxa-8,11,17-triazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2,4,6,8,11-hexaene
• CAS: 898818-47-8
• 化学式: C₂₁H₁₉N₃O₂
• 分子量: 345.401
• InChiKey: UYHLWZXLGFLELC-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (11S)-11-[(benzyloxy)methyl]-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinoline 在 间氯过氧苯甲酸 、 碳酸氢钠 作用下， 以 氯仿 、 水 为溶剂， 反应 18.0h， 生成 (11S)-11-[(benzyloxy)methyl]-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinoline 5-oxide
  参考文献：
  名称：

  WO2006/83440

  摘要：

  公开号：
• 作为产物：
  描述：

  1-[(1S)-2-(benzyloxy)-1-({[tert-butyl(dimethyl)silyl]oxy}methyl)ethyl]-2-(chloromethyl)-1H-imidazo[4,5-c]quinoline 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (11S)-11-[(benzyloxy)methyl]-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinoline
  参考文献：
  名称：

  WO2006/74003

  摘要：

  公开号：

文献信息

• Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds
  申请人：Griesgraber W. George

  公开号：US20080085895A1

  公开（公告）日：2008-04-10

  Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R 1 )— group in the fused ring at the 1-position of the imidazo ring, wherein R 1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及一种替代融合[1,2]咪唑[4,5-c]环化合物（例如咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其中在咪唑环的1位的融合环中包含—CH（—R1）—基团，其中R1包括一个官能团，例如酰胺，磺酰胺，脲，氨基甲酸酯，酯，酮，醚，上述的硫代物，磺酰，肟或羟胺，以及包含这些化合物的制药组合物，中间体，制备这些化合物的方法以及这些化合物作为免疫调节剂的用途，用于诱导动物细胞因子生物合成和治疗包括病毒和肿瘤疾病的方法。
• Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds
  申请人：Griesgraber George W.

  公开号：US20080269192A1

  公开（公告）日：2008-10-30

  Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X 1 —R 1 )-group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本文介绍了具有融合[1,2]咪唑[4,5-c]环化合物的化合物（例如咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其中在咪唑环的1-位置处具有一个—CH（—X1—R1）-基团，以及含有这些化合物的制药组合物，中间体，制备这些化合物的方法以及将这些化合物用作免疫调节剂的方法，用于诱导动物中的细胞因子生物合成以及治疗包括病毒和肿瘤性疾病在内的疾病。
• SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
  申请人：Griesgraber George W.

  公开号：US20110293654A1

  公开（公告）日：2011-12-01

  Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R 1 )— group in the fused ring at the 1-position of the imidazo ring, wherein R 1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及具有融合的[1,2]咪唑[4,5-c]环化合物（例如，咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其在咪唑环的1位处具有一个—CH（—R1）—基团，其中R1包括一个功能基团，例如酰胺，磺酰胺，脲，氨基甲酸酯，酯，酮，醚，上述的硫代物，磺酰，肟或羟胺，以及包含该化合物的制药组合物，中间体，制备该化合物的方法以及将这些化合物用作免疫调节剂的方法，用于诱导动物细胞因子生物合成并治疗包括病毒和肿瘤疾病在内的疾病。
• CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
  申请人：Griesgraber George W.

  公开号：US20110207725A1

  公开（公告）日：2011-08-25

  Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X 1 —R 1 )-group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明揭示了带有在咪唑环的1位处的融合环中的—CH(—X1—R1)-基团的融合[1,2]咪唑[4,5-c]环化合物（例如，咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），包含该化合物的制药组合物，中间体，制备该化合物的方法以及将这些化合物用作免疫调节剂的方法，用于诱导动物中的细胞因子生物合成和治疗包括病毒和肿瘤性疾病在内的疾病。
• Chiral fused [1,2]imidazo[4,5-c] ring compounds
  申请人：3M Innovative Properties Company

  公开号：US08207162B2

  公开（公告）日：2012-06-26

  Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明揭示了带有在咪唑环的1-位置上与融合环中的—CH(—X1—R1)—基团相关的化合物，例如咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉。本发明还涉及含有这些化合物的制药组合物，中间体，制备这些化合物的方法，以及这些化合物作为免疫调节剂的用途的方法，用于诱导动物中的细胞因子生物合成和治疗包括病毒性和肿瘤性疾病在内的疾病。